Polysaccharide of Escherichia coli in the Prevention of Recurrent Urinary Tract Infection: An Evidence-Based Review

• Autor(a) principal: Tinoco, Manuel
• Data de Publicação: 2018
• Outros Autores: Santos, Mélody, Reitor, Conceição, Rodrigues, Andreia, Monteiro, João
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
• Texto Completo: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9367
• topic: Adjuvants; Immunologic/therapeutic use; Escherichia coli Infections; Urinary Tract Infections; Uropathogenic Escherichia coli; Adjuvantes Imunológicos/uso terapêutico; Escherichia coli Uropatogénica; Infecções por Escherichia coli; Infecções Urinárias

Introduction: Recurrent urinary tract infection is frequent and it is related to morbidity, costs and growing antibiotic resistance. OM 8930 vaccine is composed by Escherichia coli polysaccharide and it is a possible prophylactic measure, but there is doubt as to its effectiveness.Material and Methods: We performed a systematic review in evidence-based medicine databases with rigorous bibliography selection.Results: We found an effective decrease of recurrences in test groups.Discussion: We recommend the administration of the vaccine as prophylaxis of recurrent cystitis.Conclusion: The vaccine has impact on the recurrent cystitis relapse rate. We suggest that more studies be carried out to evaluate the vaccine cost-benefit and its effectiveness in complicated urinary infections.